Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

JDRF and BD join to develop novel insulin delivery products for treatment of type 1 diabetes

The Juvenile Diabetes Research Foundation (JDRF) and BD (Becton, Dickinson and Company) announced today an innovative program aimed at improving the treatment of type 1 diabetes by developing novel insulin delivery products to enhance the use of insulin pumps.

From BD (Becton, Dickinson and Company) 20 Jan 2010

DURECT commences dosing in its POSIDUR Phase III clinical trial

DURECT Corporation announced today that it has begun dosing patients in its U.S. pivotal Phase III clinical trial to evaluate POSIDUR™ (SABER™-Bupivacaine), an investigational drug, for the treatment of post-surgical pain. The pivotal trial, referred to as BESST (Bupivacaine Effectiveness and Safety in SABER Trial), is an international, multi-center, randomized, double-blind, controlled trial evaluating the safety, efficacy, effectiveness, and pharmacokinetics of POSIDUR in patients undergoing general surgical procedures.

19 Jan 2010

Accellent reports preliminary financial information for fiscal fourth-quarter ended December 31, 2009

Accellent Inc. (the “Company”), a wholly owned subsidiary of Accellent Holdings Corp. (“Accellent”), today announced certain preliminary financial information for its fiscal fourth quarter and the full year ended December 31, 2009.

19 Jan 2010

Accellent to refinance its existing senior secured credit facilities

Accellent Inc. announced today that it has adopted a plan to refinance (the "Refinancing") its existing senior secured credit facilities and replace them with indebtedness that has longer-dated maturities. The plan, which has been unanimously approved by the Company's Board of Directors, would strengthen the Company’s capital structure by extending nearer term maturities such that the Company has no maturities until November 2013.

19 Jan 2010

Dramatically enhanced image contrast could revolutionize diagnostics and therapeutics

A Northwestern University study shows that coupling a magnetic resonance imaging (MRI) contrast agent to a nanodiamond results in dramatically enhanced signal intensity and thus vivid image contrast.

18 Jan 2010

Protectus Medical Devices and Moll Industries sign manufacturing agreement

Protectus Medical Devices, Inc. ("Protectus Medical Devices"), a developer and marketer of innovative medical devices, today announced the signing of a three-year manufacturing agreement with Moll Industries, Inc. to provide injection molded plastic manufacturing services for the Protectus Safety Syringe.

17 Jan 2010

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

Emisphere Technologies, Inc. today announced that Novo Nordisk has initiated its first Phase I clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a $2 million payment to Emisphere, whose proprietary Eligen® Technology is used in the formulation of NN9924.

13 Jan 2010

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug’s bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.

13 Jan 2010

BDSI to discuss planned BEMA Granisetron IND with the FDA

BioDelivery Sciences International, Inc. announced that the company has been granted a meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned Investigational New Drug (IND) application for BDSI’s antiemetic (anti-nausea and vomiting) product candidate, BEMA Granisetron. The meeting will take place on March 17, 2010. The company will discuss with the FDA clinical development and regulatory plans for BEMA Granisetron, which is anticipated to enter Phase 1 studies in the second quarter of 2010.

13 Jan 2010

NitricBio chooses Clinipace Worldwide to manage and conduct two phase 3 trials

Clinipace Worldwide, a global technology-driven clinical research organization (CRO), announced today that NitricBio has selected the company to manage and deploy multiple studies in support of medical applications of topical nitric oxide gas (gNO).

13 Jan 2010

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Antares Pharma, Inc. and the Population Council today announced successful results from a dose-finding Phase 2 trial for a novel contraceptive gel containing the progestin Nestorone and estradiol (NES/E2) utilizing the Antares ATD (advanced transdermal delivery) gel system. Based on this successful data, the two parties continue to expect to partner with a worldwide or regional pharmaceutical company in order to commercialize this novel contraceptive gel.

12 Jan 2010

A.P. Pharma regains compliance for continued listing on Nasdaq Capital Market

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on January 7, 2010, it received notice from the Nasdaq Stock Market (Nasdaq) confirming that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5450(a)(1).

11 Jan 2010

A.P. Pharma receives final milestone payment of $2.5M from Paul Capital Healthcare

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced it has received the final milestone payment of $2.5 million from an affiliate of Paul Capital Healthcare.

11 Jan 2010

Gerresheimer Group sets up new medical plastic systems production facility in Brazil

The Gerresheimer Group has set up a new facility for medical plastic systems in Indaiatuba (Brazil). The plant is to commence operations early in 2010. On the basis of a long-term cooperation agreement with Novo Nordisk, components will be produced with state-of-the-art technology for insulin pen systems for diabetics.

11 Jan 2010

PEPFAR's second five-year phase will strengthen healthcare systems

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has praised the recent announcement that the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) will increase its emphasis over the next five years on strengthening health systems in developing countries.

From BD (Becton, Dickinson and Company) 9 Jan 2010

Arcadia Capital Advisors files intent to purchase remaining CPEX shares at $14 per share

CPEX Pharmaceuticals, Inc. today confirmed that Arcadia Capital Advisors, LLC and its principal Richard Rofé, who hold approximately 12% of outstanding shares, have filed with the Securities and Exchange Commission (SEC) notice of intention of Mr. Rofé to make an unsolicited contingent offer to purchase the remaining shares of common stock of CPEX for $14.00 per share. Mr. Rofé indicated that any offer would require the CPEX Board of Directors to redeem the Rights under CPEX Shareholder Rights Plan.

9 Jan 2010

NexMed updates corporate activities

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today provided an update on ongoing corporate activities and the status of the Company’s NASDAQ listing.

9 Jan 2010

Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study

ACCESS PHARMACEUTICALS, INC., today announced that it has completed enrollment and evaluation of the last additional cohort of patients in the ongoing clinical study of ProLindac as a monotherapy in ovarian cancer patients who have received at least two prior platinum based treatment regimens.

8 Jan 2010

Sinexus renamed as Intersect ENT; begins clinical study on new bioabsorbable stent

Sinexus has changed its name to Intersect ENT. Intersect's initial focus is a bioabsorbable drug eluting stent to treat patients with chronic sinusitis, a debilitating condition that affects 37 million people each year and is more prevalent than heart disease or asthma.

8 Jan 2010

Pfizer and Debiopharm Group enter into co-development agreement to conduct Phase 3 trial of tremelimumab

Pfizer Inc. (Pfizer) and Debiopharm Group™ (Debiopharm) announced today that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma.

8 Jan 2010

Drug Delivery News and Research

Further Reading

JDRF and BD join to develop novel insulin delivery products for treatment of type 1 diabetes

DURECT commences dosing in its POSIDUR Phase III clinical trial

Accellent reports preliminary financial information for fiscal fourth-quarter ended December 31, 2009

Accellent to refinance its existing senior secured credit facilities

Dramatically enhanced image contrast could revolutionize diagnostics and therapeutics

Protectus Medical Devices and Moll Industries sign manufacturing agreement

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

BDSI to discuss planned BEMA Granisetron IND with the FDA

NitricBio chooses Clinipace Worldwide to manage and conduct two phase 3 trials

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

A.P. Pharma regains compliance for continued listing on Nasdaq Capital Market

A.P. Pharma receives final milestone payment of $2.5M from Paul Capital Healthcare

Gerresheimer Group sets up new medical plastic systems production facility in Brazil

PEPFAR's second five-year phase will strengthen healthcare systems

Arcadia Capital Advisors files intent to purchase remaining CPEX shares at $14 per share

NexMed updates corporate activities

Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study

Sinexus renamed as Intersect ENT; begins clinical study on new bioabsorbable stent

Pfizer and Debiopharm Group enter into co-development agreement to conduct Phase 3 trial of tremelimumab

Drug Discovery - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News